Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation

Summary

This multicentre prospective cohort enrolled 106 lung transplant recipients and measured the percentage of donor-derived cell-free DNA (ddcfDNA) in plasma by shotgun sequencing during the first three months after transplantation. Allograft failure was defined as severe CLAD, retransplantation or death from respiratory failure. According to the abstract, patients in the upper tertile of average ddcfDNA had a 6.6-fold higher risk of allograft failure (95 percent confidence interval 1.6 to 19.9) and lower peak FEV1, and they had more frequent ddcfDNA elevations that were not clinically detectable. The abstract states that the funder was the National Institutes of Health. The outcome combines several events, so the result is not specific to CLAD, and grant numbers were not read.

Details

doi

10.1016/j.ebiom.2018.12.029

pmid

30692045

authors

Agbor-Enoh S, Wang Y, Tunc I, et al.

journal

EBioMedicine

year

2019

volume

40

pages

541-553

Sources and links

• Publisher record via DOI (primary)
• PubMed 30692045

Related

Links from this record

• reports: Donor-derived cell-free DNA

Linked from (derived)

• author affiliation matches this institution (PubMed): Johns Hopkins Lung Transplant Program
• author affiliation matches this institution (PubMed): Stanford Lung Transplant Program
• author affiliation matches this institution (PubMed): Lung Transplant Program, University of Maryland Medical Center

Known gaps in this record

• full text not read (abstract only)
• funding statement and grant numbers
• author affiliations
• full author list (first three authors recorded)
• centre or centres not stated in the abstract